7JN.F POOLBEG PHARMA LS -0002
- Market cap
- EUR 44.3M
- P/E
- -
- P/B
- 5.79x
- ROE
- -66.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7JN.F undervalued?
Graham numberThe Graham number of POOLBEG PHARMA LS -0002 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
POOLBEG PHARMA LS -0002 fundamental analysis
No fundamental analysis for POOLBEG PHARMA LS -0002 yet.
POOLBEG PHARMA LS -0002 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About POOLBEG PHARMA LS -0002
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza …
Full company profilePOOLBEG PHARMA LS -0002 financial statements
POOLBEG PHARMA LS -0002 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.34M | -4.99M | -4.69M | -6.11M | -6.00M |
| EBITDA | - | -4.96M | -4.66M | -6.00M | -5.94M |
| Net Income | -2.34M | -4.69M | -3.93M | -5.79M | -5.70M |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||
| Total Assets | 23.0M | 19.3M | 15.4M | 10.2M | 9.94M |
| Total Liabilities | 438K | 966K | 986K | 974K | 1.34M |
| Shareholders' Equity | 22.6M | 18.3M | 14.4M | 9.27M | 8.60M |
| Cash & Short-term Investments | 20.9M | 16.2M | 12.2M | 7.82M | 7.71M |
| Cash Flow | |||||
| Operating Cash Flow | -2.15M | -4.37M | -4.38M | -4.65M | -4.76M |
| Capital Expenditure | 81.0K | 597K | 175K | 129K | 80.0K |
| Free Cash Flow | -2.23M | -4.97M | -4.56M | -4.78M | -4.84M |
| Ratios | |||||
| ROE | -10.3% | -25.6% | -27.2% | -62.4% | -66.2% |
| ROA | -10.1% | -24.3% | -25.5% | -56.5% | -57.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
POOLBEG PHARMA LS -0002 dividends
POOLBEG PHARMA LS -0002 has not paid dividends in the last 5 fiscal years.
Who owns POOLBEG PHARMA LS -0002
- Insiders 38.76%
- Institutions 3.99%
- Public & others 57.25%
- Shares outstanding 763M
- Free float 534M
POOLBEG PHARMA LS -0002 company profile
- Company name
- POOLBEG PHARMA LS -0002
- Ticker
- 7JN.F
- ISIN
- GB00BKPG7Z60
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- The Clubhouse Holborn, London, United Kingdom, EC4A 3AG
- Phone
- 44 20 7183 1499
- Website
- poolbegpharma.com
About POOLBEG PHARMA LS -0002
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.
POOLBEG PHARMA LS -0002 management
6- Mr. Cathal Martin FrielExecutive Chairman of The Board · born 1964
- Dr. Jeremy Skillington Ph.D.CEO & Director · born 1971
- Mr. Ian O'ConnellCFO & Director · born 1987
- Carol DaltonVice President of Investor Relations & Public Relations
- Mr. Liam TremblePrincipal Scientist
- Mr. Ross CrockettGroup Financial Controller